COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period

Yıl: 2023 Cilt: 53 Sayı: 6 Sayfa Aralığı: 1744 - 1755 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5744 İndeks Tarihi: 17-01-2024

COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period

Öz:
Background/aim:It wasaimed herein to investigate coronavirus disease (COVID-19) in cancer patients and compare hematological and solid organ cancer patients in terms of the course and outcome of this disease. Materials and methods:Data from cancer patients with laboratory-confirmed COVID-19 infection were analyzed retrospectively. Risk factors for poor prognosis and the effect of vaccination on the clinical outcomes of the patients were evaluated. Results:A total of 403 cancer patients who were diagnosed with COVID-19 between March 1st, 2021, and November 30th, 2022, were included, of whom 329 (81.6%) had solid and 74 (18.4%) had hematological cancers. Hospitalization and intensive care unit (ICU) admission rates were significantly higher in the hematological cancer patients compared to the solid organ cancer patients (73.0% vs. 35.9%, p< 0.001 and 25.7% vs. 14.0%, p= 0.013, respectively). The COVID-19-related case fatality rate (CFR) was defined as 15.4%, and it was higher in the hematologicalcancer patientsthan inthe solid organ cancer patients (23.0% vs. 13.7%, p= 0.045) and was higher in patients with metastatic/advanced disease compared to the other cancer stages (p< 0.001). In the solid organ cancergroup, hospitalization, ICU admission, and the COVID-19 CFR were higher in patients with respiratory and genitourinary cancers (p< 0.001). A total of 288 (71.8%) patients had receivedCOVID-19 vaccination; 164 (56.94%) had≤2 doses and 124 (43.06%) had≥3 doses.The hospitalization rate was higher in patients with ≤2 doses of vaccine compared to those with ≥3 doses (48.2% vs. 29.8%,p= 0.002). Patients with COVID-19- related death had higher levels of leucocyte, neutrophil, D-dimer, troponin, C-reactive protein (CRP), procalcitonin, and ferritin and lower levels of lymphocyte than the survivors. In the logistic regression analysis,the risk of COVID-19-related mortality was higher in the hematological cancer patients(OR:1.726), those who were male (OR:1.757), and with the Pre-Delta/Delta variants (OR:1.817). Conclusion:This study revealed that there is an increased risk of COVID 19 related serious events (hospitalization, ICU admission, or death) in patients with hematological cancerscompared with those who have solid organ cancers. It wasalso shown that receiving ≥3 doses of COVID-19 vaccine is more protective against severe illness and the need for hospitalization than ≤2 doses.
Anahtar Kelime: Cancer patients COVID-19 COVID-19 vaccination

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Zarifkar P, Kamath A, Robinson C, Morgulchik N, Shah SFH et al. Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis. Clinical Oncology Journal 2021; 33 (3): 180-191. https:// doi:10.1016/j.clon.2020.11.006
  • 2. Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H et al. Coronavirus disease 2019 outcomes, patient vaccination status, and cancer-related delays during the omicron wave: a brief report from the TERAVOLT analysis. Journal of Thoracic Oncology Clinical and Research Reports 2022; 3 (8): 100335. https://doi:10.1016/j.jtocrr.2022.100335
  • 3. Corti C, Antonarelli G, Scotté F, Spano JP, Barrière J et al. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review. Annals of Oncology 2022; 33 (2): 158-168. https://doi:10.1016/j.annonc.2021.10.014
  • 4. Fendler A, de Vries EGE, GeurtsvanKessel CH, Haanen JB, Wörmann B et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nature Reviews Clinical Oncology 2022; 19: 385-401. https://doi.org/10.1038/s41571- 022-00610-8
  • 5. Lee MX, Peng S, Lee ARYB, Wong SY, Tay RYK et al. Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients. Annals of the Academy of Medicine 2023; 52 (1): 8-16. https:// doi:10.47102/annals-acadmedsg.2022302
  • 6. BakounyZ,LabakiC,GroverP,AwosikaJ,GulatiSetal.COVID-19 and cancer consortium. interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19. Journal of the American Medical AssociationOncology 2023; 9 (1): 128-134. https://doi:10.1001/jamaoncol.2022.5357
  • 7. Bakouny Z, Hawley JE, Choueiri TK, Peters S, Rini BI et al. COVID-19 and cancer: current challenges and perspectives. Cancer Cell 2020 Nov 9; 38 (5): 629-646. https:// doi:10.1016/j.ccell.2020.09.018
  • 8. Stöss C, Steffani M, Pergolini I, Hartmann D, Radenkovic D et al. Impact of the COVID-19 pandemic on surgical oncology in Europe: results of a European survey. Digestive Surgery 2021; 38 (4): 259-265. https://doi:10.1159/000515186
  • 9. Giesen N, Busch E, Schalk E, Beutel G, Rüthrich MM et al. AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. European Journal of Cancer 2023; 181: 102-118. https:// doi:10.1016/j.ejca.2022.11.030
  • 10. Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P et al. Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) infection: a systematic review and meta- analysis of observational studies. The Aging Male 2020; 23 (5): 1416-24.https://doi:10.1080/13685538.2020.1774748
  • 11. Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology 2021; 14 (1): 168. https://doi:10.1186/s13045-021-01177-0
  • 12. Hingmire S, Wategaonkar R, Hegde S, Mekha M, Kulkarni R et al. Outcome of COVID-19 infection in cancer patients in Pune. South Asian Journal of Cancer 2021; 10 (1): 23-27. https:// doi:10.1055/s-0041-1731910
  • 13. de Azambuja E, Brandão M, Wildiers H, Laenen A, Aspeslagh S et al. Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. European Society for Medical Oncology Open 2020; 5 (5): 000947. https://doi:10.1136/ esmoopen-2020-000947
  • 14. Yigenoglu TN, Ata N, Altuntas F, Bascı S, Dal MS et al. The outcome of COVID-19 in patients with hematological malignancy. Journal of Medical Virology 2021; 93 (2): 1099-1104. https://doi:10.1002/jmv.26404
  • 15. Karataş A, Malkan ÜY, Velet M, Demiroğlu H, Büyükaşık Y et al. The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients. Turkish Journal of Medical Sciences 2021; 51 (4): 1647-1652. https://doi:10.3906/sag-2103-72
  • 16. Başcı S, Ata N, Altuntaş F, Yiğenoğlu TN, Dal MS et al. Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers. Internal and Emergency Medicine 2022; 17 (1): 135-139. https:// doi:10.1007/s11739-021-02784-y
  • 17. Plais H, Labruyère M, Creutin T, Nay P, Plantefeve G et al. Outcomes of patients with active cancer and COVID-19 in the intensive-care unit: a multicenter ambispective study. Frontiers in Oncology 2022; 12: 858276. https://doi:10.3389/ fonc.2022.858276
  • 18. Altuntas F, Ata N, Yigenoglu TN, Bascı S, Dal MS et al. COVID-19 in hematopoietic cell transplant recipients. Bone Marrow Transplantation 2021; 56 (4): 952-955. https:// doi:10.1038/s41409-020-01084-x
  • 19. Cesaro S, Ljungman P, Mikulska M, Hirsch HH, von Lilienfeld- Toal M et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia 2022; 36(6): 1467-1480. https://doi:10.1038/s41375-022-01578- 1
  • 20. Seneviratne SL, Wijerathne W, Yasawardene P, Somawardana B. COVID-19 in cancer patients. Transactions of the Royal Society of Tropical Medicine and Hygiene 2022;116 (9): 767- 797. https://doi:10.1093/trstmh/trac015
  • 21. Ferrari BL, Ferreira CG, Menezes M, De Marchi P, Canedo J et al. Determinants of COVID-19 mortality in patients with cancer from a community oncology practice in Brazil. JCO Global Oncology 2021; 7: 46-55. https://doi:10.1200/GO.20.00444
  • 22. Khoury E, Nevitt S, Madsen WR, Turtle L, Davies G et al. Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: a systematic review and meta-analysis. Journal of the American Medical AssociationNetwork Open 2022; 5 (5): 2210880.https:// doi:10.1001/jamanetworkopen.2022.10880
  • 23. Yasin AI, Aydin SG, Sümbül B, Koral L, Şimşek M et al. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncology 2022; 1(10): 1235-1244. https://doi:10.2217/fon-2021-1248
  • 24. Bergman P, Blennow O, Hansson L, Mielke S, Nowak P et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. eBioMedicine 2021; 74: 103705. https://doi:10.1016/j. ebiom.2021.103705
  • 25. Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H et al. Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. Journal of Thoracic Oncology 2022; 17 (2): 239-251. https://doi:10.1016/j.jtho.2021.10.015
  • 26. Fenioux C, Teixeira L, Fourati S, Melica G, Lelievre JD et al. SARS-CoV-2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents. The Journal of the American Medical Association Oncology 2022; 8 (4): 612-617. https://doi:10.1001/jamaoncol.2021.7777
  • 27. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021; 398 (10309): 1407- 1416. https://doi:10.1016/S0140-6736(21)02183-8
  • 28. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA et al. Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from Omicron, Delta, and Alpha SARS- CoV-2 variants in the United States: prospective observational study. British Medical Journal 2022; 376: 069761. https:// doi:10.1136/bmj-2021-069761
  • 29. Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: asystematic review. Journal of Medical Virology 2022; 94 (7): 2969-2976.https://doi:10.1002/ jmv.27697
APA iskender g, Mert D, Yapar Toros G, Yılmaz F, BOZAN E, Tuncbilek S, oksuzoglu b, Altuntas F, ERTEK M (2023). COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period. , 1744 - 1755. 10.55730/1300-0144.5744
Chicago iskender gülşen,Mert Duygu,Yapar Toros Göknur,Yılmaz Funda,BOZAN Ersin,Tuncbilek Semra,oksuzoglu berna,Altuntas Fevzi,ERTEK MUSTAFA COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period. (2023): 1744 - 1755. 10.55730/1300-0144.5744
MLA iskender gülşen,Mert Duygu,Yapar Toros Göknur,Yılmaz Funda,BOZAN Ersin,Tuncbilek Semra,oksuzoglu berna,Altuntas Fevzi,ERTEK MUSTAFA COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period. , 2023, ss.1744 - 1755. 10.55730/1300-0144.5744
AMA iskender g,Mert D,Yapar Toros G,Yılmaz F,BOZAN E,Tuncbilek S,oksuzoglu b,Altuntas F,ERTEK M COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period. . 2023; 1744 - 1755. 10.55730/1300-0144.5744
Vancouver iskender g,Mert D,Yapar Toros G,Yılmaz F,BOZAN E,Tuncbilek S,oksuzoglu b,Altuntas F,ERTEK M COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period. . 2023; 1744 - 1755. 10.55730/1300-0144.5744
IEEE iskender g,Mert D,Yapar Toros G,Yılmaz F,BOZAN E,Tuncbilek S,oksuzoglu b,Altuntas F,ERTEK M "COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period." , ss.1744 - 1755, 2023. 10.55730/1300-0144.5744
ISNAD iskender, gülşen vd. "COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period". (2023), 1744-1755. https://doi.org/10.55730/1300-0144.5744
APA iskender g, Mert D, Yapar Toros G, Yılmaz F, BOZAN E, Tuncbilek S, oksuzoglu b, Altuntas F, ERTEK M (2023). COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period. Turkish Journal of Medical Sciences, 53(6), 1744 - 1755. 10.55730/1300-0144.5744
Chicago iskender gülşen,Mert Duygu,Yapar Toros Göknur,Yılmaz Funda,BOZAN Ersin,Tuncbilek Semra,oksuzoglu berna,Altuntas Fevzi,ERTEK MUSTAFA COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period. Turkish Journal of Medical Sciences 53, no.6 (2023): 1744 - 1755. 10.55730/1300-0144.5744
MLA iskender gülşen,Mert Duygu,Yapar Toros Göknur,Yılmaz Funda,BOZAN Ersin,Tuncbilek Semra,oksuzoglu berna,Altuntas Fevzi,ERTEK MUSTAFA COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period. Turkish Journal of Medical Sciences, vol.53, no.6, 2023, ss.1744 - 1755. 10.55730/1300-0144.5744
AMA iskender g,Mert D,Yapar Toros G,Yılmaz F,BOZAN E,Tuncbilek S,oksuzoglu b,Altuntas F,ERTEK M COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period. Turkish Journal of Medical Sciences. 2023; 53(6): 1744 - 1755. 10.55730/1300-0144.5744
Vancouver iskender g,Mert D,Yapar Toros G,Yılmaz F,BOZAN E,Tuncbilek S,oksuzoglu b,Altuntas F,ERTEK M COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period. Turkish Journal of Medical Sciences. 2023; 53(6): 1744 - 1755. 10.55730/1300-0144.5744
IEEE iskender g,Mert D,Yapar Toros G,Yılmaz F,BOZAN E,Tuncbilek S,oksuzoglu b,Altuntas F,ERTEK M "COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period." Turkish Journal of Medical Sciences, 53, ss.1744 - 1755, 2023. 10.55730/1300-0144.5744
ISNAD iskender, gülşen vd. "COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period". Turkish Journal of Medical Sciences 53/6 (2023), 1744-1755. https://doi.org/10.55730/1300-0144.5744